Daxibotulinumtoxina

Summary

Daxibotulinumtoxina (CHEMBL3707359) is an approved unknown; indicated across 3 conditions including plantar fasciitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• Indications: 3 conditions
• Clinical trials: 11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3707359
Name	Daxibotulinumtoxina
Type	Unknown
Max phase	4

Also known as: Daxibotulinumtoxina, Daxibotulinumtoxina-lanm, Daxxify, RTI-150, RTI150, RTT150, DAXIBOTULINUMTOXINA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
plantar fasciitis	2	MONDO:0004833	EFO:1001909

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE2	5
PHASE4	2
PHASE3	2
PHASE1/PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06195241	PHASE4	RECRUITING	Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm
NCT06225492	PHASE4	COMPLETED	DaxibotulinimtoxinA for Treatment of Platysmal Neck Bands
NCT03608397	PHASE3	COMPLETED	Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)
NCT03617367	PHASE3	COMPLETED	Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)
NCT02706795	PHASE2	COMPLETED	Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical Dystonia
NCT03786770	PHASE2	COMPLETED	Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)
NCT03911102	PHASE2	COMPLETED	Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines
NCT04259086	PHASE2	COMPLETED	Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines
NCT05158166	PHASE1/PHASE2	COMPLETED	DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia
NCT06411002	PHASE2	COMPLETED	Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines
NCT06154070	Not specified	UNKNOWN	An Open Label, Study of DaxibotulinumtoxinA for Migraine Prevention

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).